These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 17598008

  • 1. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
    Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N.
    Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J, Rathgen K, Stähle H, Gansser D, Roth W.
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [Abstract] [Full Text] [Related]

  • 3. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A.
    Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
    [Abstract] [Full Text] [Related]

  • 4. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.
    Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N.
    Thromb Haemost; 2007 Aug; 98(2):333-8. PubMed ID: 17721615
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
    Li YZ, Gong GQ, Yang WH, Wang XH, Jiang ML, Zhou Y, Yang XZ, Xu YG, He GW.
    Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
    [Abstract] [Full Text] [Related]

  • 8. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.
    Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J.
    Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1885-9. PubMed ID: 20671233
    [Abstract] [Full Text] [Related]

  • 9. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
    Deinum J, Mattsson C, Inghardt T, Elg M.
    Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.
    Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K.
    J Clin Pharmacol; 2008 Dec; 48(12):1411-9. PubMed ID: 18827075
    [Abstract] [Full Text] [Related]

  • 11. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
    Baetz BE, Spinler SA.
    Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
    Stangier J, Clemens A.
    Clin Appl Thromb Hemost; 2009 Nov; 15 Suppl 1():9S-16S. PubMed ID: 19696042
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
    Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N.
    J Thromb Haemost; 2007 Jun; 5(6):1237-42. PubMed ID: 17362226
    [Abstract] [Full Text] [Related]

  • 16. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
    Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A, Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden.
    Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
    Stangier J, Stähle H, Rathgen K, Fuhr R.
    Clin Pharmacokinet; 2008 Feb; 47(1):47-59. PubMed ID: 18076218
    [Abstract] [Full Text] [Related]

  • 18. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, Lang B, Ramael S, Moschetti V, Gruenenfelder F, Reilly P, Kreuzer J.
    Lancet; 2015 Aug 15; 386(9994):680-90. PubMed ID: 26088268
    [Abstract] [Full Text] [Related]

  • 19. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
    Blommel ML, Blommel AL.
    Am J Health Syst Pharm; 2011 Aug 15; 68(16):1506-19. PubMed ID: 21817082
    [Abstract] [Full Text] [Related]

  • 20. [Monitoring of Oral Thrombin Inhibitor].
    Matsuno K, Usami T, Hatuse M, Shimizu C.
    Rinsho Byori; 2014 Oct 15; 62(10):958-64. PubMed ID: 27526541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.